Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1087-1092

  Yamamoto, Nobuyuki ^b   Tamura, Tomohide ^b   Nishiwaki, Yutaka ^b   Kurita, Yuzo ^b   Kawakami, Yoshikazu ^b   Abe, Shosaku ^b   Nakabayashi, Takehito ^b   Suzuki, Shuji ^b   Matsuda, Tamotsu ^b   Hayashi, Izumi ^b   Takahashi, Terumi ^b   Saijo, Nagahiro ^a,b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Japan Clinical Oncology Group   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; NEUTROPHILIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; ETOPOSIDE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; VOMITING;

EID: 0030859295     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ratain, M. J., Staubus, A. E., Schilsky, R. L., and Malspesis, L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res., 48: 4127-4130, 1988.
2. Egorin, M. J., Forrest, A., Belani, C. P., Ratain, M. J., Abrams, J. S., and Van Echo, D. A. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res., 49: 3129-3133, 1989.
3. Ratain, M. J., Robert, J., and van der Vijgh, W. J. Limited sampling models for doxorubicin pharmacokinetics. J. Clin. Oncol., 9: 871-876, 1991.
4. Peng, B., Boddy, A. V., Cole, M., Pearson, A. D., Chatelut, E., Rubie, H., and Newell, D. R. Comparison of methods for the estimation of carboplatin pharmacokinetics in pediatric cancer patients. Eur. J. Cancer, 31A: 1804-1810, 1995.
5. Holz, J. B., Koppler, H., Schmidt, L., Fritsh, H. W., Pfluger, K. H., and Jungclas, H. Limited sampling models for reliable estimation of area under the curve. Eur. J. Cancer, 31A: 1794-1798, 1995.
6. Jodrell, D. I., Murray, L. S., Hawtof, J., Graham, M. A., and Egorin, M. J. A comparison of methods for the limited-sampling strategy design using data from a Phase I trial of the anthrapyrazole Dup-941. Cancer Chemother. Pharmacol., 37: 356-362, 1996.
7. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
8. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaru, S., and Ohta, K. An early Phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
9. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
10. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
11. Takeuchi, S., Takamizawa, H., Takeda, Y., Okawa, T., Tamaya, Y., Noda, K., Sagawa, T., Sekiba, K., Yakushiji, M., and Taguchi, T. Clinical study of CPT-11, a camptothecin derivative, on gynecological malignancy. Proc. Am. Soc. Clin. Oncol., 11: 224, 1992.
12. Karato, A., Nakashima, H., Sasaki, Y., Yamamoto, N., Fukuda, M., Shiraishi, J., Arioka, H., Oshita, F., Ohe, Y., Tamura, T., Eguchi, K., Shinkai, T., and Saijo, N. Limited sampling models of CPT-11 and SN-38. Proc. Am. Assoc. Cancer Res., 35: 427, 1994.
13. Goto, K., Nishiwaki, Y., Saijo, N., Nakabayashi, T., Kawakami, Y., Fujita, A., Tobise, K., Abe, S., Suzuki, S., Tsuchiya, S., Takahashi, S., Hayashi, I., Noda, K., Kurita, Y., Matsuda, T., Tamura, T., and Shimoyama, M. Phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese clinical oncology group (JCOG) trial. Proc. Am. Soc. Clin. Oncol., 14: 362, 1995.
14. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
15. WHO. WHO Handbook for Reporting Results of Cancer Treatment No. 48. Geneva: WHO, 1979.
16. Tobinai, K., Kohno, A., Shimada, Y., Watanabe, T., Tamura, T., Takeyama, K., Narabayashi, M., Fukutomi, T., Kondo, H., Shimoyama, M., Suemasu, K., and members of the clinical trial committee of the Japan clinical oncology group. Toxicity grading criteria of the Japan clinical oncology group. Jpn. J. Clin. Oncol., 23: 250-257, 1993.
17. Yamamoto, N., Tamura, T., Karato, A., Uenaka, K., Eguchi, K., Shinkai, T., Ohe, Y., Oshita, F., Arioka, H., Nakashima, H., et al. CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn. J. Cancer Res., 85: 972-977, 1994.
18. Ratain, M. J., Rosner, G., Duggan, D., Bonneterre, J., Bugat, R., Tubiana-Hulin, M., and Mahieu-Boyé A. Population pharmacodynamic study of single-agent doxorubicin in women with stage III breast cancer. Proc. Am. Soc. Clin. Oncol., 12: 140, 1993.
19. Gay C., Lokiec F., Canal P., Bonneterre, J., Bugat, R., Tubiana-Hulin, M., and Mathieu-Boué, A. Pharmacokinetics and pharmacodynamics of the camptothecin analogue CPT-11 during Phase II studies. Proc. Am. Assoc. Cancer Res., 35: 243, 1994.
20. Sheiner, L. B., and Beal, S. L. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci., 71: 1344-1348, 1982.
21. Sasaki, Y., Hakusui, H., Mizuno, S., Morita, M., Miya, T., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., and Saijo, N. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res., 86: 101-110, 1995.
22. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J. M., Mahjoubi, M., Hrait, P., Armand, J. P., Bugat, R., et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann. Oncol., 6: 141-151, 1995.